BEVERLY, MASS. (PRWEB) FEBRUARY 21, 2019
On January 7th, 2019, Orthopedic surgeon Dr. Mario Cahueque and Neurosurgeon Dr. Enrique Azmitia implanted SpineFrontier’s SacroFuse system in conjunction with NanoFUSE’s Orthobiologic during a surgery at the Hospital Centro Medico in Guatemala City, Guatemala. The case represents the first time that either SacroFuse or NanoFUSE have been used in Latin America.
Dr. Cahueque performed a sacroiliac arthrodesis for sacroiliac dysfunction in a 70-year old male that had been suffering lower back pain for over a year. Sacroiliac pain and dysfunction is a frequent pathology especially in patients with lumbar fusion. Until the surgery date, the patient was receiving a conservative treatment with intra-articular injections and physical therapy.
Dr. Cahueque used three SacroFuse screws to fuse the sacroiliac joint. The SacroFuse is an innovative Less Exposure Surgery (LES™) technology designed to leverage the familiarity of existing techniques while minimizing tissue disruption. The fusion was enhanced by the NanoFUSE Orthobiologic, which is the only FDA-cleared, biologic combination of Demineralized Bone Matrix (DBM) plus Bioactive Glass.
Dr. Cahueque reported that the patient has made an excellent recovery. He believes this first case in Guatemala is significant. “This new less invasive treatment opens new options for the treatment of this pathology for patients with chronic sacroiliac joint pain,” Dr. Cahueque said. He has already planned his next SacroFuse/NanoFUSE case and is grateful for the support of Francisco Gramajo of Moalconver who helped make the SacroFuse surgery in Guatemala possible.
About SpineFrontier Inc.
SpineFrontier is a growing medical device technology company that designs and develops implants and instruments for spine surgery, based on the Less Exposure Surgery (LES) philosophy. These technologies and techniques are designed to allow for outpatient surgery due to minimal disruption of normal tissue. SpineFrontier is headquartered in Malden, Mass. It is a KICVentures portfolio company and the leader in LES technologies.
About NanoFUSE Biologics
NanoFUSE is the synergistic blend of osteoinductive DBM combined with the osteostimulative properties of bioactive glass. NanoFUSE is the only FDA-cleared combination of DBM and bioactive glass and is indicated for use in all orthopedic surgery. NanoFUSE Biologics is a KICVentures portfolio company, distributed by SpineFrontier.
KICVentures is a private investment company founded in 2005 by Harvard-trained Orthopedic Surgeon & Professor Dr. Kingsley R. Chin, who brings unique experience at the intersection of medicine, business and information technology. KICVentures is equipped with a strong advantage in identifying niche healthcare opportunities. It is the parent company of NanoFUSE and SpineFrontier and is headquartered in Boston, Mass.